Xenon Pharmaceuticals Inc.
XENE· Nasdaq
XENEXenon Pharmaceuticals Inc.
Filed Mar 6, 2019 · 10-K · 65 days after period end · 0001564590-19-006514
derived · Computed from the longer spans the company filed.
| Metric | Q4 2018dderived from reported figures | Q4 2017 | Q4 2016 | Q4 2015 |
|---|---|---|---|---|
| Revenue | — | $16.00K | $376.00K | $3.23M |
| Net Income | -$8.56M | -$8.07M | -$6.00M | -$3.94M |
| EPS Diluted | — | -$0.45 | -$0.34 | -$0.27 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
ended Dec 31, 2018 · filed Mar 6, 2019 · 65 d after period end
